	US 12,435,308 B2
	Immunomodulation by amniotic fluid mesenchymal stem cells
Jan Talts, Staffanstorp (SE); and Kåre Engkilde, Værløse (DK)
Assigned to Amniotics AB, Lund (SE)
Filed by Amniotics AB, Lund (SE)
Filed on Nov. 5, 2021, as Appl. No. 17/453,744.
Claims priority of provisional application 63/110,825, filed on Nov. 6, 2020.
Prior Publication US 2022/0145250 A1, May 12, 2022
Int. Cl. C12N 5/0783 (2010.01); C12N 5/078 (2010.01); C12N 5/0786 (2010.01)

CPC C12N 5/0636 (2013.01) [C12N 5/0634 (2013.01); C12N 5/0645 (2013.01); C12N 2502/025 (2013.01); C12N 2506/025 (2013.01)]

12 Claims

1. A method of reducing T cell activation in a population of activated T cells comprising:

isolating lung term amniotic fluid mesenchymal stem cells (TAF-MSCs), which express CD248, DDR-1 and LRRC38, from human amniotic fluid by cell sorting for CD248, DDR-1 and LRRC38 to generate a population of isolated lung TAF-MSCs; and

culturing the population of isolated lung TAF-MSCs with the population of activated T cells for a time sufficient to reduce T cell activation below a level of T cell activation of a population of activated T cells that are not co-cultured with the isolated lung TAF-MSCs.